Thomas K Equels bought $1K of AIM stock

Thomas K Equels, CEO & President of AIM ImmunoTech Inc. (AIM), bought 5,900 shares of AIM stock worth $1K, per an SEC Form 4 filed Sep 15, 2026.

It was an open-market purchase.

The trade happened on Sep 14, 2026, 1 day before it was made public.

AIM has moved -30.5% since the trade date, from $0.22 to $0.15 (Nov 6, 2026 close).